drugset / Trial / NCT01331525
The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer
Phase 2
Completed
42 enrolled
University Hospital Southampton NHS Foundation Trust
Bristol-Myers Squibb · collabCancer Research UK · collabInstitute of Cancer Research, United Kingdom · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial will investigate the addition of an antibody (Ipilimumab) to conventional Carboplatin and Etoposide chemotherapy in extensive stage small cell lung cancer. The primary objective is to establish the progression free survival at 1 year.
Timeline
- Start
- 2011-06
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 10 mg/kg | Intravenous |